Abstract
References
- 1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Twenty-eighth Informational Supplement M100-S28, Wayne, PA (USA), 2018.
- 2. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 9.0 http://www.eucast.org/clinical_breakpoints/ (March 2019, date last accessed)
- 3. Mirza HC. Glycopeptide resistance in S. aureus. In: Enany S, Alexander LE, eds. The rise of virulence and antibiotic resistance in Staphylococcus aureus. Croatia: InTech; 2017. p. 43-59.
- 4. Gardete S, Tomasz A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest. 2014; 124(7): 2836-40.
Comment on : 'Distribution, phenotypic characterisation and antibiogram of bacterial species from hospital environment in Nigeria: Public health implications'
Abstract
Sir,
I read with
interest the article by Onuoha et al. entitled 'Distribution, phenotypic
characterisation and antibiogram of bacterial species from hospital environment
in Nigeria: Public health implications'. The authors performed antimicrobial susceptibility
testing for the bacteria that were isolated from various surfaces of a federal
teaching hospital. The authors used disk diffusion method for the detection of
vancomycin resistance among S. aureus
isolates. According to current guidelines, the disk diffusion test with
vancomycin is unreliable and should not be used for the detection of vancomycin
resistance in S. aureus. Clinical and
Laboratory standards Institute (CLSI) and European
Committee on Antimicrobial Susceptibility Testing (EUCAST) recommend vancomycin
MIC testing to determine the susceptibility of staphylococci to vancomycin.
The authors also performed antimicrobial susceptibility
testing for Salmonella spp. and Shigella spp. isolates. They included cephalothin
(a first generation cephalosporin), cefuroxime (a second generation
cephalosporin), streptomycin and gentamicin (aminoglycosides) among the
antimicrobial agents tested against the isolates of Salmonella spp. and Shigella
spp. According to CLSI guidelines, first and second generation cephalosporins,
cephamycins and aminoglycosides may appear active in vitro, but these agents
are clinically ineffective and shouldn't be reported as susceptible.
References
- 1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Twenty-eighth Informational Supplement M100-S28, Wayne, PA (USA), 2018.
- 2. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 9.0 http://www.eucast.org/clinical_breakpoints/ (March 2019, date last accessed)
- 3. Mirza HC. Glycopeptide resistance in S. aureus. In: Enany S, Alexander LE, eds. The rise of virulence and antibiotic resistance in Staphylococcus aureus. Croatia: InTech; 2017. p. 43-59.
- 4. Gardete S, Tomasz A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest. 2014; 124(7): 2836-40.
Details
| Primary Language | English |
|---|---|
| Subjects | Clinical Sciences |
| Journal Section | Letter to Editor |
| Authors | |
| Publication Date | June 30, 2019 |
| Published in Issue | Year 2019 Volume: 4 Issue: 2 |
Cite
Creative Commons Attribution Non-Commercial License: The articles in the Journal of Immunology and Clinical Microbiology are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.